{"filing":{"accession_number":"0001193125-26-322208","cik":"0001691082","ticker":"LBRX","company_name":"LB PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-28","primary_document":"d156920d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526322208/d156920d8k.htm"},"events":[{"id":21441,"run_id":19339,"accession_number":"0001193125-26-322208","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"LB Pharmaceuticals entered into a Securities Purchase Agreement on July 28, 2026, to issue 3,577,560 shares of common stock and pre-funded warrants to purchase 715,513 additional shares in a private placement for approximately $150 million in gross proceeds at $34.94 per share to institutional investors under Section 4(a)(2) exemption without registration.","company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21087,"accession_number":"0001193125-26-322208","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"LB Pharmaceuticals entered into a Securities Purchase Agreement on July 28, 2026, to issue 3,577,560 shares of common stock and pre-funded warrants to purchase 715,513 additional shares in a private placement for approximately $150 million in gross proceeds. This is a classic unregistered equity issuance (private placement) with dilutive warrants, fitting the definition of dilutive_issuance. The magnitude ($150M) and the explicit use of pre-funded warrants with minimal exercise prices ($0.0001) are hallmarks of this event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T12:06:47.433991+00:00","company_name":"","ticker":null,"filing_date":""},{"id":21088,"accession_number":"0001193125-26-322208","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"LB Pharmaceuticals disclosed a $150 million private placement of 3,577,560 shares of common stock and pre-funded warrants to institutional investors at $34.94 per share, conducted under Section 4(a)(2) exemption without registration. This is a classic dilutive equity issuance that materially affects shareholder ownership and is a significant capital-raising event for a biopharmaceutical company in clinical development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T12:06:47.433991+00:00","company_name":"","ticker":null,"filing_date":""},{"id":21089,"accession_number":"0001193125-26-322208","item_number":"7.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"LB Pharmaceuticals announced a $150 million private placement of 3,577,560 shares of common stock and pre-funded warrants to institutional investors at $34.94 per share. This is an unregistered equity issuance to a limited group of investors, which is a classic dilutive private placement. The magnitude ($150M) and the explicit statement that securities \"have not been registered under the Securities Act\" confirm this is a material dilutive capital raise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T12:06:47.433991+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21087,"accession_number":"0001193125-26-322208","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"LB Pharmaceuticals entered into a Securities Purchase Agreement on July 28, 2026, to issue 3,577,560 shares of common stock and pre-funded warrants to purchase 715,513 additional shares in a private placement for approximately $150 million in gross proceeds. This is a classic unregistered equity issuance (private placement) with dilutive warrants, fitting the definition of dilutive_issuance. The magnitude ($150M) and the explicit use of pre-funded warrants with minimal exercise prices ($0.0001) are hallmarks of this event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T12:06:47.433991+00:00","company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","filing_date":"2026-07-29"},{"id":21088,"accession_number":"0001193125-26-322208","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"LB Pharmaceuticals disclosed a $150 million private placement of 3,577,560 shares of common stock and pre-funded warrants to institutional investors at $34.94 per share, conducted under Section 4(a)(2) exemption without registration. This is a classic dilutive equity issuance that materially affects shareholder ownership and is a significant capital-raising event for a biopharmaceutical company in clinical development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T12:06:47.433991+00:00","company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","filing_date":"2026-07-29"},{"id":21089,"accession_number":"0001193125-26-322208","item_number":"7.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"LB Pharmaceuticals announced a $150 million private placement of 3,577,560 shares of common stock and pre-funded warrants to institutional investors at $34.94 per share. This is an unregistered equity issuance to a limited group of investors, which is a classic dilutive private placement. The magnitude ($150M) and the explicit statement that securities \"have not been registered under the Securities Act\" confirm this is a material dilutive capital raise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T12:06:47.433991+00:00","company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","filing_date":"2026-07-29"}]}